Loading
Decitabine (Dacogen) is an infusion that loosens the chemical silencing of genes in myelodysplastic syndromes and acute myeloid leukaemia, helping the bone marrow work again. An oral version combined with cedazuridine has its own record.
Decitabine was approved by the FDA in 2006 for myelodysplastic syndromes of all FAB subtypes and IPSS intermediate-1, intermediate-2 and high-risk groups, on a randomised trial of 170 patients in which decitabine plus supportive care produced responses and delayed progression to AML compared with supportive care alone. The EU authorised Dacogen in 2012 for newly diagnosed AML in adults aged 65 and over not eligible for standard induction (DACO-016). It is the hypomethylating partner for venetoclax in unfit AML alongside azacitidine, and the oral fixed-dose combination decitabine-cedazuridine (Inqovi, 2020) delivers equivalent exposure. Myelosuppression is universal early in treatment and responses typically take four to six cycles.
Incorporated into DNA after phosphorylation and traps DNA methyltransferase, causing genome-wide hypomethylation that re-expresses silenced genes and drives differentiation or apoptosis.
1.Decitabine slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2006 | Myelodysplastic syndromes, all FAB subtypes and IPSS intermediate-1 to high risk |
| EU | 2012 | Newly diagnosed de novo or secondary AML in adults 65 and over not candidates for standard induction |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Decitabine" OR ABSTRACT:"Decitabine" OR TITLE:"Dacogen" OR ABSTRACT:"Dacogen" OR TITLE:"5-aza-2'-deoxycytidine" OR ABSTRACT:"5-aza-2'-deoxycytidine") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Decitabine, not a curated reading list.
Shares Secondary and therapy-related acute myeloid leukaemia, Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia in older or unfit patients, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.
Shares Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab., Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS).
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia in older or unfit patients, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Decitabine + cedazuridine (oral), Acute myeloid leukaemia in older or unfit patients, Azacitidine, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia.